Interní Med. 2008; 10(5): 224-226

Dual action of parathormone and bone

prof. MUDr. Petr Broulík DrSc
III. interní klinika VFN a 1. LF UK, Praha

PTH is a hormone that increases the plasmatic level of calcium, maintains the level by mobilisation of calcium from bones with the help of osteoclastic resorption. Receptors for PTH and rP are situated on a cell membrane of osteoblasts, preosteoclasts. The bone involvement-bone changes caused by PTH over secretion are described as hyperparathyroid osteodystrophy. Unusual variability and nonconsistance of bone changes are unfortunately the main cause why such a high number of PHPT is recognized very late. PTH in a surplus is very aggressive towards bones, it dilutes bone mineral, stimulates osteoklasts and fibrous rebuilding of bones, leads to cyst formation and to formation of large brown tumours. Though hyperparathyroid osteodystrophy is a generalized disease, it does not involve the skeleton symmetrically, some regions remain practically intact; in other bones changes of all kind may be accumulated. In PHPT a bone turnover is increased, mainly in cortical bone, so the most specific and the most frequent X-ray finding is subperiostal resorption of radial and ulnar surface of distal hand phalanges. A small amount of PTH given in pulses behaves completely differerently. It activates preferentially osteoblasts, cells that form bones and only a little cells resorbing bones (osteoclasts). It increases the level of bone remodelation, increases new bone formation more than resorption.

Keywords: parathormon, osteoclastic resorption, hyperparathyroid osteodystrophy, anabolic activity of small doses of parathormon

Published: June 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Broulík P. Dual action of parathormone and bone. Interní Med. 2008;10(5):224-226.
Download citation

References

  1. Brockstedt, RH, Chritiansen P, Mosekilde L. Reconstruction of cortical bone remodeling in untreated primary hyperparathyroidism and following surgery. Bone 1955; 16: 109-111. Go to original source...
  2. Broulík P, Adámek S, Tvrdoň J, Libánský P, Raška I. Primární hyperparatyreóza. Postgraduální medicína 2007; 9: 711-715.
  3. Brown EM. The pathophysiology of primary hyperparathyroidism. J Bone Miner Res 2002; 17: 24-29.
  4. Dauphine RT, Riggs BL, Scholz DA. Back pain and vertebral crush fractures. An unemphasized mode of presentation for primary hyperparthyrodism. Ann Intern Med 1975; 83: 365-367. Go to original source... Go to PubMed...
  5. Hodsman A, Bauer D, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endcr Rev 2005; 26: 688-703. Go to original source... Go to PubMed...
  6. Khosla, S, Melton, LJ, Wermers RA, et al. Primary hyperparathyroidism and the risk of fracture. A population based study. J Bone Miner res 1999; 14: 1700-1707. Go to original source... Go to PubMed...
  7. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21: 115-137. Go to original source...
  8. Marx SJ. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med 2000; 343: 1863-1875. Go to original source... Go to PubMed...
  9. Neer R, Arnaud C, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441. Go to original source... Go to PubMed...
  10. Silverberg SJ, Bilezikian JP. Clinical presentation of primary hyperparathyroidism in the United States. In Bilezikian JP The parathyroids 2nd ed. New York: Raven Press 2001: 349-360. Go to original source...
  11. Speigel AM, Weinstein LS. Inherited diseases involving G protein-coupled receptors. Annu Rev Med 2004; 55: 27-39. Go to original source... Go to PubMed...
  12. Wilson RJ, Rao S, et al. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. Ann Intern Med 1988; 109: 959-962. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.